
Philip D Harvey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6941992/publications.pdf Version: 2024-02-01



DHILLD D HADVEY

#	Article	IF	CITATIONS
1	Confidence, accuracy judgments and feedback in schizophrenia and bipolar disorder: a time series network analysis. Psychological Medicine, 2023, 53, 4200-4209.	2.7	2
2	Ecological momentary facial emotion recognition in psychotic disorders. Psychological Medicine, 2022, 52, 2531-2539.	2.7	10
3	Understanding the Course and Correlates of Depression in Older People Undergoing Caregiving Stress. American Journal of Geriatric Psychiatry, 2022, 30, 158-160.	0.6	0
4	The relationship between cognition and functioning in schizophrenia: A semi-systematic review. Schizophrenia Research: Cognition, 2022, 27, 100217.	0.7	32
5	Improvements in Cognitive Performance With Computerized Training in Older People With and Without Cognitive Impairment: Synergistic Effects of Skills-Focused and Cognitive-Focused Strategies. American Journal of Geriatric Psychiatry, 2022, 30, 717-726.	0.6	6
6	Remote digital phenotyping in serious mental illness: Focus on negative symptoms, mood symptoms, and self-awareness. Biomarkers in Neuropsychiatry, 2022, 6, 100047.	0.7	5
7	Complete blood count inflammatory markers in treatment-resistant schizophrenia: Evidence of association between treatment responsiveness and levels of inflammation. Psychiatry Research, 2022, 308, 114382.	1.7	20
8	Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia. Schizophrenia Bulletin, 2022, 48, 609-619.	2.3	22
9	A Longitudinal Examination of Real-World Sedentary Behavior in Adults with Schizophrenia-Spectrum Disorders in a Clinical Trial of Combined Oxytocin and Cognitive Behavioral Social Skills Training. Behavioral Sciences (Basel, Switzerland), 2022, 12, 60.	1.0	2
10	Brief battery of the Social Cognition Psychometric Evaluation study (BB-SCOPE): Development and validation in schizophrenia spectrum disorders. Journal of Psychiatric Research, 2022, 150, 307-316.	1.5	4
11	A genome-wide association study of suicide attempts in the million veterans program identifies evidence of pan-ancestry and ancestry-specific risk loci. Molecular Psychiatry, 2022, 27, 2264-2272.	4.1	35
12	Momentary severity of psychotic symptoms predicts overestimation of competence in domains of everyday activities and work in schizophrenia: An ecological momentary assessment study. Psychiatry Research, 2022, 310, 114487.	1.7	11
13	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. Schizophrenia Research: Cognition, 2022, 29, 100249.	0.7	23
14	Mobile facial affect recognition and real-time social experiences in serious mental illness. Schizophrenia Research: Cognition, 2022, 29, 100253.	0.7	0
15	Heterogeneity of social cognitive performance in autism and schizophrenia. Autism Research, 2022, 15, 1522-1534.	2.1	6
16	Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC) Innovations in Clinical Neuroscience, 2022, 19, 26-32.	0.1	3
17	Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics and Telepsychiatry Use During COVID-19 Pandemic. CNS Spectrums, 2022, 27, 230-230.	0.7	2
18	The association of momentary sad moods, concurrent productive behaviour, and global functional outcomes: a 30-day ecological momentary assessment study of people with bipolar illness. Cognitive Neuropsychiatry, 2022, 27, 342-355.	0.7	4

#	Article	IF	CITATIONS
19	Examining the association of life course neurocognitive ability with real-world functioning in schizophrenia-spectrum disorders. Schizophrenia Research: Cognition, 2022, 29, 100254.	0.7	3
20	Digital Therapeutics to Enhance Cognition in Major Depression: How Can We Make the Cognitive Gains Translate Into Functional Improvements?. American Journal of Psychiatry, 2022, 179, 445-447.	4.0	5
21	Revisiting how people with schizophrenia spend their days: Associations of lifetime milestone achievements with daily activities examined with Ecological Momentary Assessment. Psychiatry Research Communications, 2022, 2, 100060.	0.2	1
22	Pathways from performance monitoring to negative symptoms and functional outcomes in psychotic disorders. Psychological Medicine, 2021, 51, 2012-2022.	2.7	13
23	High-intensity Focused Ultrasound for the Treatment of Prostate Cancer: A National Cohort Study Focusing on the Development of Stricture and Fistulae. European Urology Focus, 2021, 7, 340-346.	1.6	13
24	Prior traumaâ€related experiences predict the development of posttraumatic stress disorder after a new traumatic event. Depression and Anxiety, 2021, 38, 40-47.	2.0	16
25	The Computerized Functional Skills Assessment and Training Program: Sensitivity to Global Cognitive Impairment, Correlations With Cognitive Abilities, and Factor Structure. American Journal of Geriatric Psychiatry, 2021, 29, 395-404.	0.6	6
26	Real world sedentary behavior and activity levels in patients with schizophrenia and controls: An ecological momentary assessment study. Mental Health and Physical Activity, 2021, 20, 100364.	0.9	23
27	Better functional capacity and cognitive performance in clozapine responders compared to non-responders: A cross-sectional study. Schizophrenia Research, 2021, 229, 134-136.	1.1	2
28	Genome-Wide Association Studies of Schizophrenia and Bipolar Disorder in a Diverse Cohort of US Veterans. Schizophrenia Bulletin, 2021, 47, 517-529.	2.3	48
29	Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. NPJ Schizophrenia, 2021, 7, 16.	2.0	42
30	COVID-19-related psychological distress and engagement in preventative behaviors among individuals with severe mental illnesses. NPJ Schizophrenia, 2021, 7, 7.	2.0	16
31	Situational context influences the degree of hostile attributions made by individuals with schizophrenia or autism spectrum disorder. British Journal of Clinical Psychology, 2021, 60, 160-176.	1.7	4
32	Self-reported social functioning and social cognition in schizophrenia and bipolar disorder: Using ecological momentary assessment to identify the origin of bias. Schizophrenia Research, 2021, 230, 17-23.	1.1	30
33	Ecological momentary assessment as a measurement tool in depression trials. Journal of Psychiatric Research, 2021, 136, 256-264.	1.5	24
34	Integration of peripheral transcriptomics, genomics, and interactomics following trauma identifies causal genes for symptoms of post-traumatic stress and major depression. Molecular Psychiatry, 2021, 26, 3077-3092.	4.1	15
35	Addressing Patients' Unmet Needs to Improve Outcomes in Schizophrenia. Journal of Clinical Psychiatry, 2021, 82, .	1.1	2
36	Transcriptome-wide association study of post-trauma symptom trajectories identified GRIN3B as a potential biomarker for PTSD development. Neuropsychopharmacology, 2021, 46, 1811-1820.	2.8	15

#	Article	IF	CITATIONS
37	Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder. Journal of Clinical Psychopharmacology, 2021, Publish Ahead of Print, 501-503.	0.7	3
38	Evidence for avolition in bipolar disorder? A 30-day ecological momentary assessment comparison of daily activities in bipolar disorder and schizophrenia. Psychiatry Research, 2021, 300, 113924.	1.7	20
39	Cooperative studies Program (CSP) #572: A study of serious mental illness in veterans as a pathway to personalized medicine in schizophrenia and bipolar illness. Personalized Medicine in Psychiatry, 2021, 27-28, 100078.	0.1	0
40	Development of novel measures for Alzheimer's disease prevention trials (NoMAD). Contemporary Clinical Trials, 2021, 106, 106425.	0.8	4
41	Ecological momentary assessment of interpersonal theory of suicide constructs in people experiencing psychotic symptoms. Journal of Psychiatric Research, 2021, 140, 496-503.	1.5	11
42	Using a Meta-cognitive Wisconsin Card Sorting Test to measure introspective accuracy and biases in schizophrenia and bipolar disorder. Journal of Psychiatric Research, 2021, 140, 436-442.	1.5	18
43	Cognitive Endophenotypes: Powerful Tools for Modern Neuropsychiatric Genomics Research. Biological Psychiatry, 2021, 90, 354-355.	0.7	0
44	Computational methods for integrative evaluation of confidence, accuracy, and reaction time in facial affect recognition in schizophrenia. Schizophrenia Research: Cognition, 2021, 25, 100196.	0.7	8
45	Autistic symptoms in people with schizophrenia: Neurocognitive, socio-cognitive, clinical and real-world functional characteristics of individuals without autistic features. Schizophrenia Research, 2021, 236, 12-18.	1.1	4
46	Performance-based assessment of social skills in a large sample of participants with schizophrenia, bipolar disorder and healthy controls: Correlates of social competence and social appropriateness. Schizophrenia Research, 2021, 236, 80-86.	1.1	8
47	A cross-diagnostic study of adherence to ecological momentary assessment: Comparisons across study length and daily survey frequency find that early adherence is a potent predictor of study-long adherence. Personalized Medicine in Psychiatry, 2021, 29-30, 100085.	0.1	8
48	Social cognition, neurocognition, symptomatology, functional competences and outcomes in people with schizophrenia – A network analysis perspective. Journal of Psychiatric Research, 2021, 144, 8-13.	1.5	17
49	Daily Ecological Momentary Assessments of happy and sad moods in people with schizophrenia and bipolar disorders: What do participants who are never sad think about their activities and abilities?. Schizophrenia Research: Cognition, 2021, 26, 100202.	0.7	16
50	The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry, 2021, 20, 4-33.	4.8	153
51	Lifetime employment in schizophrenia: correlates of developing long term unemployment after being employed before. Cognitive Neuropsychiatry, 2021, 26, 95-106.	0.7	4
52	Remote Ecological Momentary Testing of Learning and Memory in Adults With Serious Mental Illness. Schizophrenia Bulletin, 2021, 47, 740-750.	2.3	15
53	The relationship between substance use, prior trauma history, and risk of developing post-traumatic stress disorder in the immediate aftermath of civilian trauma. Journal of Psychiatric Research, 2021, 144, 345-352.	1.5	2
54	Capturing Clinical Symptoms with Ecological Momentary Assessment: Convergence of Momentary Reports of Psychotic and Mood Symptoms with Diagnoses and Standard Clinical Assessments. Innovations in Clinical Neuroscience, 2021, 18, 24-30.	0.1	5

#	Article	IF	CITATIONS
55	Validity of remote administration of the MATRICS Consensus Cognitive Battery for individuals with severe mental illness. Schizophrenia Research: Cognition, 2021, 27, 100226.	0.7	2
56	Schizophrenia in Older Adults. , 2021, , 4374-4382.		0
57	Neurocognition and social cognition in patients with schizophrenia spectrum disorders with and without a history of violence: results of a multinational European study. Translational Psychiatry, 2021, 11, 620.	2.4	12
58	Childhood Trauma Associations With the Interpersonal Psychological Theory of Suicide and Social Cognitive Biases in Psychotic Disorders. Journal of Nervous and Mental Disease, 2021, Publish Ahead of Print, .	0.5	5
59	Confidence, performance, and accuracy of self-assessment of social cognition: A comparison of schizophrenia patients and healthy controls. Schizophrenia Research: Cognition, 2020, 19, 100133.	0.7	32
60	Training engagement, baseline cognitive functioning, and cognitive gains with computerized cognitive training: A cross-diagnostic study. Schizophrenia Research: Cognition, 2020, 19, 100150.	0.7	20
61	Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder. Journal of Affective Disorders, 2020, 260, 550-556.	2.0	2
62	Comprehensive comparison of social cognitive performance in autism spectrum disorder and schizophrenia. Psychological Medicine, 2020, 50, 2557-2565.	2.7	64
63	Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional expression. Schizophrenia Research, 2020, 215, 352-356.	1.1	19
64	Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis. Current Medical Research and Opinion, 2020, 36, 117-124.	0.9	7
65	Neurocognition and social cognition training as treatments for violence and aggression in people with severe mental illness. CNS Spectrums, 2020, 25, 145-153.	0.7	14
66	Pharmacological treatment of violence in schizophrenia. CNS Spectrums, 2020, 25, 207-215.	0.7	13
67	Depression predicts self assessment of social function in both patients with schizophrenia and healthy people. Psychiatry Research, 2020, 284, 112681.	1.7	22
68	Cognition, Social Cognition, and Functional Capacity in Early-Onset Schizophrenia. Child and Adolescent Psychiatric Clinics of North America, 2020, 29, 171-182.	1.0	33
69	Correlates of loneliness among persons with psychotic disorders. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 549-559.	1.6	31
70	Genomeâ€wide association study of cognitive performance in U.S. veterans with schizophrenia or bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 181-194.	1.1	17
71	Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8â€week, multicenter, doubleâ€blind, randomized controlled study. Neuropsychopharmacology Reports, 2020, 40, 63-72.	1.1	12
72	Autistic symptoms predict social cognitive performance in patients with schizophrenia Schizophrenia Research, 2020, 215, 113-119.	1.1	22

#	Article	IF	CITATIONS
73	Older versus middle-aged adults with schizophrenia: Executive functioning and community outcomes. Schizophrenia Research, 2020, 216, 547-549.	1.1	5
74	M120. IMPAIRED CLINICAL INSIGHT AS A PREDICTOR OF RELAPSE IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S180-S181.	2.3	0
75	S221. THE EFFICACY OF LUMATEPERONE 42 MG IN THE TREATMENT OF SCHIZOPHRENIA SYMPTOMS ASSOCIATED WITH SOCIAL FUNCTIONING: POST HOC ANALYSIS OF AN ACUTE PLACEBO- AND ACTIVE-CONTROLLED TRIAL. Schizophrenia Bulletin, 2020, 46, S123-S123.	2.3	0
76	S223. DETERMINANTS OF SUSTAINED UNEMPLOYMENT IN FORMERLY EMPLOYED SCHIZOPHRENIA PATIENTS. Schizophrenia Bulletin, 2020, 46, S123-S124.	2.3	0
77	Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. Comprehensive Psychiatry, 2020, 102, 152195.	1.5	5
78	S173. GENOME-WIDE ASSOCIATION STUDIES OF SCHIZOPHRENIA AND BIPOLAR DISORDER IN A DIVERSE COHORT OF US VETERANS. Schizophrenia Bulletin, 2020, 46, S103-S103.	2.3	1
79	Depression, hostility, attributional biases, and paranoia in schizophrenia and healthy controls: intercorrelations and associations with self-assessment of social functioning. Psychiatry Research, 2020, 293, 113388.	1.7	1
80	Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures. Schizophrenia Research, 2020, 223, 297-304.	1.1	9
81	Requisite Skills and the Meaningful Measurement of Cognition. JAMA Psychiatry, 2020, 77, 1103.	6.0	0
82	Overconfidence in social cognitive decision making: Correlations with social cognitive and neurocognitive performance in participants with schizophrenia and healthy individuals. Schizophrenia Research, 2020, 224, 51-57.	1.1	18
83	Neighborhood socioeconomic status and racial disparities in schizophrenia: An exploration of domains of functioning. Schizophrenia Research, 2020, 224, 95-101.	1.1	9
84	Emotional determinants of life-space through GPS and ecological momentary assessment in schizophrenia: What gets people out of the house?. Schizophrenia Research, 2020, 224, 67-73.	1.1	26
85	Major Neuropsychological Impairments in Schizophrenia Patients: Clinical Implications. Current Psychiatry Reports, 2020, 22, 59.	2.1	6
86	O1.6. AFFECTIVE DETERMINANTS OF LIFE-SPACE THROUGH GPS AND ECOLOGICAL MOMENTARY ASSESSMENT IN SCHIZOPHRENIA: WHAT GETS PEOPLE OUT OF THE HOUSE?. Schizophrenia Bulletin, 2020, 46, S3-S3.	2.3	0
87	Measuring mentalizing: A comparison of scoring methods for the hinting task. International Journal of Methods in Psychiatric Research, 2020, 29, e1827.	1.1	9
88	An Array of Studies Addressing Cognition and Cognitively Defined Neuropsychiatric Conditions: Many More Connections Than You Might Think. American Journal of Psychiatry, 2020, 177, 491-496.	4.0	2
89	Emerging 5-HT receptor antagonists for the treatment of Schizophrenia. Expert Opinion on Emerging Drugs, 2020, 25, 189-200.	1.0	15
90	A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills. Journal of Visualized Experiments, 2020, , .	0.2	3

#	Article	IF	CITATIONS
91	Autistic Symptoms and Social Cognition Predict Real-World Outcomes in Patients With Schizophrenia. Frontiers in Psychiatry, 2020, 11, 524.	1.3	23
92	Psychometric properties of the Observable Social Cognition Rating Scale (OSCARS): Self-report and informant-rated social cognitive abilities in schizophrenia. Psychiatry Research, 2020, 286, 112891.	1.7	13
93	Cyberbullying and Its Relationship to Current Symptoms and History of Early Life Trauma. Journal of Clinical Psychiatry, 2020, 81, .	1.1	11
94	Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial. Clinical Drug Investigation, 2020, 40, 377-385.	1.1	14
95	Suicidal ideation, behavior, and mortality in male and female US veterans with severe mental illness. Journal of Affective Disorders, 2020, 267, 144-152.	2.0	13
96	The Impact of Intellectual Disability and Autism Spectrum Disorder on Restraint and Seclusion in Pre-Adolescent Psychiatric Inpatients. Journal of Mental Health Research in Intellectual Disabilities, 2020, 13, 86-109.	1.3	7
97	A Longitudinal Investigation of the Effects of the COVID-19 Pandemic on the Mental Health of Individuals with Pre-existing Severe Mental Illnesses. Psychiatry Research, 2020, 294, 113493.	1.7	99
98	Evaluation of a Novel Technology-Based Program Designed to Assess and Train Everyday Skills in Older Adults. Innovation in Aging, 2020, 4, igaa052.	0.0	17
99	DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMER'S DISEASE SPECTRUM. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-5.	1.5	8
100	Assessing the Real-Time Mental Health Challenges of COVID-19 in Individuals With Serious Mental Illnesses: Protocol for a Quantitative Study. JMIR Research Protocols, 2020, 9, e19203.	0.5	15
101	Schizophrenia in Older Adults. , 2020, , .		0
102	Cardiovascular, endothelial function, and immune markers in response to treatment with a polysaccharide in HIV adults in a randomized, double-blind placebo-controlled trial. Journal of Clinical and Translational Research, 2020, 5, 140-147.	0.3	2
103	Helping older adults overcome the challenges of technology. , 2020, 19, .		3
104	Paranoia and interpersonal functioning across the continuum from healthy to pathological – Network analysis. British Journal of Clinical Psychology, 2019, 58, 19-34.	1.7	29
105	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. Archives of Clinical Neuropsychology, 2019, 34, 539-547.	0.3	4
106	What Do People With Schizophrenia Do All Day? Ecological Momentary Assessment of Real-World Functioning in Schizophrenia. Schizophrenia Bulletin, 2019, 46, 242-251.	2.3	64
107	Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment. Journal of Experimental Psychopathology, 2019, 10, 204380871986569.	0.4	58
108	S123. PREDICTORS OF SOCIAL FUNCTIONING IN PATIENTS WITH HIGHER AND LOWER LEVELS OF REDUCED EMOTIONAL EXPERIENCE: SOCIAL COGNITION, SOCIAL COMPETENCE, AND SYMPTOM SEVERITY. Schizophrenia Bulletin, 2019, 45, S353-S353.	2.3	0

#	Article	IF	CITATIONS
109	GPS mobility as a digital biomarker of negative symptoms in schizophrenia: a case control study. Npj Digital Medicine, 2019, 2, 108.	5.7	74
110	F53. IMPROVED FUNCTIONAL CAPACITY AND COGNITIVE PERFORMANCE IN CLOZAPINE RESPONDERS COMPARED TO NON-RESPONDERS. Schizophrenia Bulletin, 2019, 45, S275-S276.	2.3	1
111	S11. GENETIC INFLUENCES ON LACK OF INSIGHT: THE ROLE OF CATECHOL-O-METHYLTRANSFERASE (COMT) GENE POLYMORPHISMS. Schizophrenia Bulletin, 2019, 45, S310-S310.	2.3	0
112	S43. SADDER BUT WISER: DEPRESSION OUTWEIGHS SEX AND SCHIZOPHRENIA IN SELF ASSESSMENT OF INTERPERSONAL FUNCTIONING. Schizophrenia Bulletin, 2019, 45, S322-S323.	2.3	0
113	S93. GENOMICS OF SUICIDAL IDEATION AND BEHAVIOR IN VETERANS WITH SCHIZOPHRENIA AND BIPOLAR ILLNESS. Schizophrenia Bulletin, 2019, 45, S342-S342.	2.3	0
114	O5.7. VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT IN PATIENTS WITH SCHIZOPHRENIA: CORRELATES OF PERFORMANCE OF SOLITARY AND SOCIALLY RELEVANT TASKS. Schizophrenia Bulletin, 2019, 45, S175-S175.	2.3	1
115	O6.6. REAL WORLD SEDENTARY BEHAVIOR AND ACTIVITY LEVELS IN PATIENTS WITH SCHIZOPHRENIA AND CONTROLS DERIVED FROM ECOLOGICAL MOMENTARY ASSESSMENT. Schizophrenia Bulletin, 2019, 45, S178-S178.	2.3	3
116	Depression and reduced emotional experience in schizophrenia: Correlations with self-reported and informant-rated everyday social functioning. Journal of Experimental Psychopathology, 2019, 10, 204380871982931.	0.4	6
117	O4.4. CONFIDENCE, PERFORMANCE, AND ACCURACY OF SELF-ASSESSMENT OF SOCIAL COGNITION: A COMPARISON OF SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS. Schizophrenia Bulletin, 2019, 45, S170-S170.	2.3	0
118	Cognition, social cognition, and Self-assessment in schizophrenia: prediction of different elements of everyday functional outcomes. CNS Spectrums, 2019, 24, 88-93.	0.7	45
119	Smoking Cannabis and Acquired Impairments in Cognition: Starting Early Seems Like a Really Bad Idea. American Journal of Psychiatry, 2019, 176, 90-91.	4.0	4
120	The International Consortium Investigating Neurocognition in Bipolar Disorder (ICONIC ―BD). Bipolar Disorders, 2019, 21, 6-10.	1.1	12
121	Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder. American Journal of Psychiatry, 2019, 176, 307-314.	4.0	24
122	Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes. Psychiatry Research, 2019, 277, 58-63.	1.7	10
123	Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). Schizophrenia Research, 2019, 210, 30-38.	1.1	7
124	Functional deficits in attenuated psychosis syndrome and related conditions: Current and future treatment options. Schizophrenia Research: Cognition, 2019, 17, 100152.	0.7	6
125	Cognition and disability in schizophrenia: cognitionâ€related skills deficits and decisionâ€making challenges add to morbidity. World Psychiatry, 2019, 18, 165-167.	4.8	27
126	Autism symptoms, depression, and active social avoidance in schizophrenia: Association with self-reports and informant assessments of everyday functioning. Journal of Psychiatric Research, 2019, 115, 36-42.	1.5	50

#	Article	IF	CITATIONS
127	Assessment of social cognition. , 2019, , 219-247.		Ο
128	Shape of Training Review: an impact assessment for UK gastroenterology trainees. Frontline Gastroenterology, 2019, 10, 356-363.	0.9	32
129	Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8â€week, doubleâ€blind, multicenter, randomized controlled study. Neuropsychopharmacology Reports, 2019, 39, 173-182.	1.1	15
130	Glutamate modulators for treatment of schizophrenia. Personalized Medicine in Psychiatry, 2019, 15-16, 1-12.	0.1	8
131	Predictors of social functioning in patients with higher and lower levels of reduced emotional experience: Social cognition, social competence, and symptom severity. Schizophrenia Research, 2019, 206, 271-276.	1.1	21
132	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. CNS Spectrums, 2019, 24, 154-162.	0.7	18
133	Impaired introspective accuracy in schizophrenia: an independent predictor of functional outcomes. Cognitive Neuropsychiatry, 2019, 24, 28-39.	0.7	38
134	Domains of cognition and their assessment. Dialogues in Clinical Neuroscience, 2019, 21, 227-237.	1.8	251
135	Schizophrenia in Older Adults. , 2019, , 1-9.		0
136	Associations of independent living and labor force participation with impairment indicators in schizophrenia and bipolar disorder at 20-year follow-up. Schizophrenia Research, 2018, 197, 150-155.	1.1	44
137	Interpersonal beliefs related to suicide and facial emotion processing in psychotic disorders. Journal of Psychiatric Research, 2018, 100, 107-112.	1.5	25
138	Self-assessment of social cognitive ability in schizophrenia: Association with social cognitive test performance, informant assessments of social cognitive ability, and everyday outcomes. Schizophrenia Research, 2018, 199, 75-82.	1.1	65
139	No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. European Heart Journal, 2018, 39, 374-381.	1.0	57
140	Social Skills Training for Negative Symptoms of Schizophrenia. Schizophrenia Bulletin, 2018, 44, 472-474.	2.3	24
141	Suicidal ideation and behavior in US veterans with schizophrenia or bipolar disorder. Journal of Psychiatric Research, 2018, 102, 216-222.	1.5	26
142	Social Cognition Psychometric Evaluation: Results of the Final Validation Study. Schizophrenia Bulletin, 2018, 44, 737-748.	2.3	187
143	Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder. Journal of Clinical Psychopharmacology, 2018, 38, 200-206.	0.7	13
144	Cognitive and functional deficits in people with schizophrenia: Evidence for accelerated or exaggerated aging?. Schizophrenia Research, 2018, 196, 14-21.	1.1	61

#	Article	IF	CITATIONS
145	Associations of suicidality with cognitive ability and cognitive insight in outpatients with Schizophrenia. Schizophrenia Research, 2018, 192, 340-344.	1.1	33
146	What Is So Different About Psychotic Patients Who Have Extremely Long Institutional Stays?. American Journal of Geriatric Psychiatry, 2018, 26, 198-199.	0.6	0
147	A novel cognitive assessment paradigm to detect Pre-mild cognitive impairment (PreMCI) and the relationship to biological markers of Alzheimer's disease. Journal of Psychiatric Research, 2018, 96, 33-38.	1.5	26
148	Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectrums, 2018, 23, 370-377.	0.7	28
149	Thought, language, and communication deficits and association with everyday functional outcomes among community-dwelling middle-aged and older adults with schizophrenia. Schizophrenia Research, 2018, 196, 29-34.	1.1	20
150	F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE. Schizophrenia Bulletin, 2018, 44, S242-S243.	2.3	0
151	F250. DEPRESSION IN SCHIZOPHRENIA: CORRELATIONS WITH OBJECTIVE AND SUBJECTIVE QUALITY OF LIFE OUTCOMES. Schizophrenia Bulletin, 2018, 44, S320-S320.	2.3	0
152	S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY. Schizophrenia Bulletin, 2018, 44, S353-S353.	2.3	1
153	24.4 COGNITION AND COMMUNICATION AS DETERMINANTS OF ADAPTIVE DEFICITS IN LATE LIFE SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S40-S40.	2.3	0
154	Cigarette Smoking, Cognitive Performance, and Severe Mental Illness: Quitting Smoking Really Does Seem to Matter. American Journal of Psychiatry, 2018, 175, 1054-1055.	4.0	4
155	Social cognition and short-term prediction of suicidal ideation in schizophrenia. Psychiatry Research, 2018, 270, 13-19.	1.7	23
156	Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms. Journal of Clinical Psychiatry, 2018, 79, .	1.1	24
157	Cognitive and functional deficits in bipolar disorder and schizophrenia as a function of the presence and history of psychosis. Bipolar Disorders, 2018, 20, 604-613.	1.1	31
158	Social cognitive impairments in individuals with schizophrenia vary in severity. Journal of Psychiatric Research, 2018, 104, 65-71.	1.5	33
159	Neural correlates of social cognitive introspective accuracy in schizophrenia. Schizophrenia Research, 2018, 202, 166-172.	1.1	30
160	The Course of Cognition and Functioning in Patients at Ultrahigh Risk of Developing Psychosis. JAMA Psychiatry, 2018, 75, 882.	6.0	3
161	Controversies in Computerized Cognitive Training. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 907-915.	1.1	63
162	Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia?. Journal of Psychiatric Research, 2018, 104, 124-129.	1.5	63

#	Article	IF	CITATIONS
163	T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY. Schizophrenia Bulletin, 2018, 44, S159-S159.	2.3	0
164	Evaluating social skill in individuals with schizophrenia with the brief impression questionnaire (BIQ). Psychiatry Research, 2018, 269, 38-44.	1.7	2
165	Associations of Age and Gender with Negative Symptom Factors and Functioning Among Middle-Aged and Older Adults with Schizophrenia. American Journal of Geriatric Psychiatry, 2018, 26, 1215-1219.	0.6	16
166	T235. SELF ASSESSMENT OF SOCIAL COGNITIVE ABILITY IN SCHIZOPHRENIA: ASSOCIATION WITH SOCIAL COGNITIVE TEST PERFORMANCE, INFORMANT ASSESSMENTS OF SOCIAL COGNITIVE ABILITY, AND EVERYDAY OUTCOMES. Schizophrenia Bulletin, 2018, 44, S208-S208.	2.3	0
167	Social Cognition and Neurocognition in Schizophrenia and Healthy Controls: Intercorrelations of Performance and Effects of Manipulations Aimed at Increasing Task Difficulty. Frontiers in Psychiatry, 2018, 9, 356.	1.3	31
168	Combining training leads to better results: Implications for clinical delivery of computerized cognitive and social cognitive training. Schizophrenia Research, 2018, 202, 48-49.	1.1	1
169	Correlates of risk factors for reduced life expectancy in schizophrenia: Is it possible to develop a predictor profile?. Schizophrenia Research, 2018, 201, 388-392.	1.1	15
170	The bias toward intentionality in schizophrenia: Automaticity, context, and relationships to symptoms and functioning Journal of Abnormal Psychology, 2018, 127, 503-512.	2.0	17
171	Validation of the tablet-administered Brief Assessment of Cognition (BAC App). Schizophrenia Research, 2017, 181, 100-106.	1.1	62
172	Assessing functional performance using computer-based simulations of everyday activities. Schizophrenia Research, 2017, 183, 130-136.	1.1	22
173	Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study. Schizophrenia Research, 2017, 185, 137-143.	1.1	31
174	Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder. Journal of Affective Disorders, 2017, 213, 105-111.	2.0	15
175	Exploratory analysis of normative performance on the UCSD Performanceâ€Based Skills Assessmentâ€Brief. Psychiatry Research, 2017, 256, 150-155.	1.7	16
176	Placebo Response and Practice Effects in Schizophrenia Cognition Trials. JAMA Psychiatry, 2017, 74, 807.	6.0	34
177	Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments. International Clinical Psychopharmacology, 2017, 32, 72-79.	0.9	10
178	Twentyâ€year progression of body mass index in a countyâ€wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. Bipolar Disorders, 2017, 19, 336-343.	1.1	52
179	A Novel Method for Direct Assessment of Everyday Competence Among Older Adults. Journal of Alzheimer's Disease, 2017, 57, 1229-1238.	1.2	27
180	Social cognition psychometric evaluation (SCOPE) in people with early psychosis: A preliminary study. Schizophrenia Research, 2017, 190, 136-143.	1.1	53

#	Article	IF	CITATIONS
181	Impact of genotyping errors on statistical power of association tests in genomic analyses: A case study. Genetic Epidemiology, 2017, 41, 152-162.	0.6	12
182	The Effect of Age, Race, and Sex on Social Cognitive Performance in Individuals With Schizophrenia. Journal of Nervous and Mental Disease, 2017, 205, 346-352.	0.5	30
183	M36. Social Cognition Psychometric Evaluation (SCOPE): Results: Of the Final Validation Study. Schizophrenia Bulletin, 2017, 43, S224-S225.	2.3	6
184	M33. Recognition of Fearful Faces Depends on Depressive Symptoms in Schizophrenia. Schizophrenia Bulletin, 2017, 43, S223-S223.	2.3	0
185	Inflammation in Schizophrenia: What It Means and How to Treat It. American Journal of Geriatric Psychiatry, 2017, 25, 62-63.	0.6	2
186	Measuring and Facilitating Client Engagement with Financial Incentives: Implications for Improving Clinical Outcomes in a Mental Health Setting. Community Mental Health Journal, 2017, 53, 501-509.	1.1	4
187	Self-assessment of social cognitive ability in individuals with schizophrenia: Appraising task difficulty and allocation of effort. Schizophrenia Research, 2017, 179, 85-90.	1.1	24
188	Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia. Frontiers in Psychiatry, 2017, 8, 177.	1.3	25
189	61.4 Neural Correlates of Introspective Accuracy in Schizophrenia. Schizophrenia Bulletin, 2017, 43, S36-S37.	2.3	Ο
190	M25. Development and Validation of the Brief Assessment of Validation in Schizophrenia (BAC-App). Schizophrenia Bulletin, 2017, 43, S220-S220.	2.3	2
191	Schizophrenia and Related Conditions in Late Life \hat{a} †. , 2017, , .		Ο
192	61.1 Introspective Accuracy as a Predictor of Real-World Outcomes. Schizophrenia Bulletin, 2017, 43, S35-S36.	2.3	6
193	Health status and mobility limitations are associated with residential and employment status in schizophrenia and bipolar disorder. Journal of Psychiatric Research, 2017, 94, 180-185.	1.5	24
194	Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer's Disease Spectrum. Innovations in Clinical Neuroscience, 2017, 14, 30-39.	0.1	6
195	Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience. Innovations in Clinical Neuroscience, 2017, 14, 18-22.	0.1	39
196	Insight and Treatment Outcomes in Schizophrenia: Analysis of a Long-term, Double-blind Study Comparing Lurasidone and Quetiapine XR. Innovations in Clinical Neuroscience, 2017, 14, 23-29.	0.1	3
197	Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency. Innovations in Clinical Neuroscience, 2017, 14, 30-40.	0.1	61
198	Randomized Prospective Double-Blind Studies to Evaluate the Cognitive Effects of Inositol-Stabilized Arginine Silicate in Healthy Physically Active Adults. Nutrients, 2016, 8, 736.	1.7	13

#	Article	IF	CITATIONS
199	Lurasidone Effects on Cognition and Functional Capacity in Schizophrenia. Clinical Neuropsychopharmacology and Therapeutics, 2016, 7, 11-19.	0.3	0
200	Revisiting the validity of measures of social cognitive bias in schizophrenia: Additional results from the Social Cognition Psychometric Evaluation (SCOPE) study. British Journal of Clinical Psychology, 2016, 55, 441-454.	1.7	39
201	Treatment resistant schizophrenia: Course of brain structure and function. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 70, 111-116.	2.5	23
202	Paranoid individuals with schizophrenia show greater social cognitive bias and worse social functioning than non-paranoid individuals with schizophrenia. Schizophrenia Research: Cognition, 2016, 3, 33-38.	0.7	59
203	Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain, Behavior, and Immunity, 2016, 56, 281-288.	2.0	102
204	Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis. Schizophrenia Bulletin, 2016, 42, 1234-1242.	2.3	17
205	Does neuropsychological performance impact on real-life functional achievements in obsessive-compulsive disorder? A preliminary study. International Journal of Psychiatry in Clinical Practice, 2016, 20, 224-231.	1.2	7
206	Validation of a Computerized test of Functional Capacity. Schizophrenia Research, 2016, 175, 90-96.	1.1	53
207	Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia. Schizophrenia Research: Cognition, 2016, 5, 7-12.	0.7	6
208	Depression in Schizophrenia: Associations With Cognition, Functional Capacity, Everyday Functioning, and Self-Assessment. Schizophrenia Bulletin, 2016, 43, sbw103.	2.3	43
209	Social cognition in schizophrenia: Factor structure of emotion processing and theory of mind. Psychiatry Research, 2016, 242, 150-156.	1.7	41
210	Social Cognition Psychometric Evaluation: Results of the Initial Psychometric Study. Schizophrenia Bulletin, 2016, 42, 494-504.	2.3	219
211	A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness. Psychoneuroendocrinology, 2016, 64, 22-30.	1.3	42
212	Neurocognitive insight and objective cognitive functioning in schizophrenia. Schizophrenia Research, 2016, 171, 131-136.	1.1	32
213	Factor structure of cognition and functional capacity in two studies of schizophrenia and bipolar disorder: Implications for genomic studies Neuropsychology, 2016, 30, 28-39.	1.0	33
214	A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing–Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychiatry, 2016, 77, 799-806.	1.1	22
215	Designing a Web-Based Application to Train Aging Adults to Successfully Use Technologies Important to Independent Living. Lecture Notes in Computer Science, 2016, , 289-299.	1.0	0
216	Dr Kantrowitz and Colleagues Reply. Journal of Clinical Psychiatry, 2016, 77, e1353-e1353.	1.1	0

#	Article	IF	CITATIONS
217	Factors predicting work outcome in Japanese patients with schizophrenia: role of multiple functioning levels. Schizophrenia Research: Cognition, 2015, 2, 105-112.	0.7	15
218	Self-assessment in schizophrenia: Accuracy of evaluation of cognition and everyday functioning Neuropsychology, 2015, 29, 675-682.	1.0	93
219	The Happy Older Latinos are Active (HOLA) health promotion and prevention study: study protocol for a pilot randomized controlled trial. Trials, 2015, 16, 579.	0.7	20
220	The clinical utility of lurasidone in schizophrenia: patient considerations. Neuropsychiatric Disease and Treatment, 2015, 11, 1103.	1.0	7
221	Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder. Neuropsychopharmacology, 2015, 40, 446-453.	2.8	83
222	The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: An analysis of the CATIE Schizophrenia Trial. Schizophrenia Research, 2015, 166, 110-114.	1.1	11
223	Understanding Symbol Coding in Schizophrenia. Biological Psychiatry, 2015, 78, 744-746.	0.7	5
224	Absence of bias in clinician ratings of everyday functioning among African American, Hispanic and Caucasian patients with schizophrenia. Psychiatry Research, 2015, 229, 347-352.	1.7	6
225	Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophrenia Bulletin, 2015, 42, sbv111.	2.3	34
226	Factors influencing self-assessment of cognition and functioning in bipolar disorder: a preliminary study. Cognitive Neuropsychiatry, 2015, 20, 361-371.	0.7	27
227	Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. Schizophrenia Research, 2015, 165, 76-82.	1.1	150
228	Editorial. Schizophrenia Research: Cognition, 2015, 2, 1.	0.7	2
229	Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 103-111.	1.2	191
230	High velocity circuit resistance training improves cognition, psychiatric symptoms and neuromuscular performance in overweight outpatients with severe mental illness. Psychiatry Research, 2015, 229, 295-301.	1.7	47
231	Social cognition, social competence, negative symptoms and social outcomes: Inter-relationships in people with schizophrenia. Journal of Psychiatric Research, 2015, 68, 254-260.	1.5	107
232	Insight and subjective measures of quality of life in chronic schizophrenia. Schizophrenia Research: Cognition, 2015, 2, 127-132.	0.7	47
233	The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization. Schizophrenia Research, 2015, 166, 69-79.	1.1	20
234	Factors influencing self-assessment of cognition and functioning in schizophrenia: Implications for treatment studies. European Neuropsychopharmacology, 2015, 25, 185-191.	0.3	75

#	Article	IF	CITATIONS
235	Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. European Neuropsychopharmacology, 2015, 25, 176-184.	0.3	44
236	Methods for Delivering and Evaluating the Efficacy of Cognitive Enhancement. Handbook of Experimental Pharmacology, 2015, 228, 5-25.	0.9	3
237	Cognitive performance, symptom severity, and survival among patients with schizophrenia spectrum disorder: A prospective 15-year study. Schizophrenia Research, 2015, 169, 141-146.	1.1	14
238	Improving the understanding of the link between cognition and functional capacity in schizophrenia and bipolar disorder. Schizophrenia Research, 2015, 169, 121-127.	1.1	13
239	Effect of lurasidone dose on cognition in patients with schizophrenia: Post-hoc analysis of a long-term, double-blind continuation study. Schizophrenia Research, 2015, 166, 334-338.	1.1	24
240	Latest Developments in Cognitive Functioning in Mood and Anxiety Disorders. Current Behavioral Neuroscience Reports, 2015, 2, 165-172.	0.6	0
241	Clozapine improves the orienting of attention in schizophrenia. Schizophrenia Research, 2015, 168, 285-291.	1.1	30
242	ASSESSMENT OF AGE-RELATED DIFFERENCES IN FUNCTIONAL CAPACITY USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT). journal of prevention of Alzheimer's disease, The, 2015, 2, 1-7.	1.5	23
243	Restraint and seclusion as therapeutic interventions: changes across consecutive admissions. Journal of Psychiatric Intensive Care, 2014, 10, 84-92.	0.2	2
244	Physical performance and disability in schizophrenia. Schizophrenia Research: Cognition, 2014, 1, 112-121.	0.7	56
245	Utility of the UCSD Performance-based Skills Assessment-Brief Japanese version: discriminative ability and relation to neurocognition. Schizophrenia Research: Cognition, 2014, 1, 137-143.	0.7	22
246	Social competence versus negative symptoms as predictors of real world social functioning in schizophrenia. Schizophrenia Research, 2014, 160, 136-141.	1.1	100
247	The genetics of functional disability in schizophrenia and bipolar illness: Methods and initial results for VA cooperative study #572. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 381-389.	1.1	36
248	Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia. Bipolar Disorders, 2014, 16, 422-431.	1.1	71
249	Treatment resistance and other complicating factors in the management of schizophrenia. CNS Spectrums, 2014, 19, 13-24.	0.7	7
250	The evolution of illness phases in schizophrenia: A non-parametric item response analysis of the Positive and Negative Syndrome Scale. Schizophrenia Research: Cognition, 2014, 1, 53-89.	0.7	5
251	Cognition in schizophrenia: Past, present, and future. Schizophrenia Research: Cognition, 2014, 1, e1-e9.	0.7	181
252	A longitudinal examination of the moderating effects of symptoms on the relationship between functional competence and real world functional performance in Schizophrenia. Schizophrenia Research: Cognition, 2014, 1, 90-95.	0.7	36

#	Article	IF	CITATIONS
253	The Social Cognition Psychometric Evaluation Study: Results of the Expert Survey and RAND Panel. Schizophrenia Bulletin, 2014, 40, 813-823.	2.3	369
254	The Brief Assessment of Cognition In Affective Disorders (BAC-A):Performance of patients with bipolar depression and healthy controls. Journal of Affective Disorders, 2014, 166, 86-92.	2.0	43
255	Depression, deficits in functional capacity, and impaired glycemic control in urban African Americans with type 2 diabetes. Journal of Psychiatric Research, 2014, 52, 21-27.	1.5	19
256	Latent semantic variables are associated with formal thought disorder and adaptive behavior in older inpatients with schizophrenia. Cortex, 2014, 55, 88-96.	1.1	66
257	Development of the Spanish Brief-version of the University of California Performance Skills Assessment (Sp-UPSA-Brief) in patients with schizophrenia and bipolar disorder. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2014, 7, 113-120.	0.2	2
258	Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and self-reports. Journal of Psychiatric Research, 2014, 57, 51-57.	1.5	35
259	Virtual reality functional capacity assessment in schizophrenia: Preliminary data regarding feasibility and correlations with cognitive and functional capacity performance. Schizophrenia Research: Cognition, 2014, 1, e21-e26.	0.7	44
260	The course and correlates of everyday functioning in schizophrenia. Schizophrenia Research: Cognition, 2014, 1, e47-e52.	0.7	40
261	Neurocognition, functional capacity, and functional outcomes: The cost of inexperience. Schizophrenia Research, 2014, 152, 430-434.	1.1	47
262	Discovery of previously undetected intellectual disability by psychological assessment: A study of consecutively referred child and adolescent psychiatric inpatients. Research in Developmental Disabilities, 2014, 35, 1705-1710.	1.2	7
263	The course of vocational functioning in patients with schizophrenia: Re-examining social drift. Schizophrenia Research: Cognition, 2014, 1, e41-e46.	0.7	17
264	Development of a Virtual Reality Assessment of Everyday Living Skills. Journal of Visualized Experiments, 2014, , .	0.2	18
265	Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectrums, 2014, 19, 197-205.	0.7	35
266	Disability in Schizophrenia. Journal of Clinical Psychiatry, 2014, 75, 15-20.	1.1	38
267	What Is the Evidence for Changes in Cognition and Functioning Over the Lifespan in Patients With Schizophrenia?. Journal of Clinical Psychiatry, 2014, 75, 34-38.	1.1	58
268	Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder. Schizophrenia Research, 2013, 144, 146-150.	1.1	46
269	Hospitalization and psychosis: Influences on the course of cognition and everyday functioning in people with schizophrenia. Neurobiology of Disease, 2013, 53, 18-25.	2.1	39
270	Subscale structure for the Positive and Negative Syndrome Scale (PANSS): A proposed solution focused on clinical validity. Psychiatry Research, 2013, 205, 137-142.	1.7	20

#	Article	IF	CITATIONS
271	Vocational functioning in schizotypal and paranoid personality disorders. Psychiatry Research, 2013, 210, 498-504.	1.7	24
272	Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia. Schizophrenia Research, 2013, 146, 244-248.	1.1	59
273	Validation of a European Spanish-version of the University of California performance Skills Assessment (Sp-UPSA) in patients with schizophrenia and bipolar disorder. Schizophrenia Research, 2013, 150, 421-426.	1.1	31
274	Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension. European Neuropsychopharmacology, 2013, 23, 1373-1382.	0.3	69
275	Self-assessment of functional ability in schizophrenia: Milestone achievement and its relationship to accuracy of self-evaluation. Psychiatry Research, 2013, 207, 19-24.	1.7	51
276	Commentary on "Cognition in schizophrenia― European Neuropsychopharmacology, 2013, 23, 781-783.	0.3	1
277	Assessment of everyday functioning in schizophrenia: Implications for treatments aimed at negative symptoms. Schizophrenia Research, 2013, 150, 353-355.	1.1	53
278	The convergence between self-reports and observer ratings of financial skills and direct assessment of financial capabilities in patients with schizophrenia: More detail is not always better. Schizophrenia Research, 2013, 147, 86-90.	1.1	17
279	Prevalence and Precursors of the use of Restraint and Seclusion in a Private Psychiatric Hospital: Comparison of Child and Adolescent Patients. Administration and Policy in Mental Health and Mental Health Services Research, 2013, 40, 224-231.	1.2	27
280	Cognitive aspects of schizophrenia. Wiley Interdisciplinary Reviews: Cognitive Science, 2013, 4, 599-608.	1.4	4
281	Factor Structure of Neurocognition and Functional Capacity in Schizophrenia: A Multidimensional Examination of Temporal Stability. Journal of the International Neuropsychological Society, 2013, 19, 656-663.	1.2	25
282	Comparative impairments across schizophrenia and bipolar disorder. , 2013, , 50-68.		3
283	Cognition and work functioning in schizophrenia. , 2013, , 98-109.		6
284	Cognitive impairment and symptom dimensions in psychosis. , 2013, , 69-84.		2
285	Systematic Study of Structured Diagnostic Procedures in Outpatient Psychiatric Rehabilitation: A Three-year, Three-cohort Study of the Stability of Psychiatric Diagnoses. Innovations in Clinical Neuroscience, 2013, 10, 14-9.	0.1	15
286	Combined Cognitive Remediation and Functional Skills Training for Schizophrenia: Effects on Cognition, Functional Competence, and Real-World Behavior. American Journal of Psychiatry, 2012, 169, 710-718.	4.0	269
287	Cognitive impairment in schizophrenia: profile, course, and neurobiological determinants. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 433-445.	1.0	15
288	Impairment in Functional Capacity as an Endophenotype Candidate in Severe Mental Illness. Schizophrenia Bulletin, 2012, 38, 1318-1326.	2.3	27

#	Article	IF	CITATIONS
289	Diagnosis of schizophrenia: Consistency across information sources and stability of the condition. Schizophrenia Research, 2012, 140, 9-14.	1.1	20
290	Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: Overlap between milestones and specificity of ratings. Journal of Psychiatric Research, 2012, 46, 1546-1552.	1.5	66
291	Age-Associated Differences in Cognitive Performance in Older Patients With Schizophrenia: A Comparison With Healthy Older Adults. American Journal of Geriatric Psychiatry, 2012, 20, 29-40.	0.6	66
292	Schizophrenia in Later Life. American Journal of Geriatric Psychiatry, 2012, 20, 1-4.	0.6	7
293	Cognitive Enhancement in Schizophrenia. Psychiatric Clinics of North America, 2012, 35, 683-698.	0.7	48
294	Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry, 2012, 11, 73-79.	4.8	233
295	The influence of demographic factors on functional capacity and everyday functional outcomes in schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 467-475.	0.8	30
296	Cognitive deficits, obesity and disability in schizophrenia. Translational Neuroscience, 2012, 3, .	0.7	8
297	Predictors of the accuracy of self assessment of everyday functioning in people with schizophrenia. Schizophrenia Research, 2012, 137, 190-195.	1.1	107
298	Functional impairment in people with schizophrenia: Focus on employability and eligibility for disability compensation. Schizophrenia Research, 2012, 140, 1-8.	1.1	134
299	Determinants of occupational and residential functioning in bipolar disorder. Journal of Affective Disorders, 2012, 136, 812-818.	2.0	24
300	Metaâ€analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disorders, 2012, 14, 217-226.	1.1	254
301	Functional Outcomes Assessment Scales. , 2012, , 33-38.		1
302	Clinical applications of neuropsychological assessment. Dialogues in Clinical Neuroscience, 2012, 14, 91-99.	1.8	157
303	Cognitive remediation in severe mental illness. Innovations in Clinical Neuroscience, 2012, 9, 27-30.	0.1	2
304	Technology, society, and mental illness: challenges and opportunities for assessment and treatment. Innovations in Clinical Neuroscience, 2012, 9, 47-50.	0.1	28
305	Development and Cross-Validation of the UPSA Short Form for the Performance-Based Functional Assessment of Patients With Mild Cognitive Impairment and Alzheimer Disease. American Journal of Geriatric Psychiatry, 2011, 19, 915-922.	0.6	50
306	Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophrenia Research, 2011, 125, 161-168.	1.1	183

#	Article	IF	CITATIONS
307	Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophrenia Research, 2011, 127, 188-194.	1.1	86
308	Assessing everyday functioning in schizophrenia: Not all informants seem equally informative. Schizophrenia Research, 2011, 131, 250-255.	1.1	131
309	Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia. Schizophrenia Research, 2011, 132, 165-170.	1.1	74
310	Performance-based assessment of functional skills in severe mental illness: Results of a large-scale study in China. Journal of Psychiatric Research, 2011, 45, 1089-1094.	1.5	48
311	Evaluation of Functionally Meaningful Measures for Clinical Trials of Cognition Enhancement in Schizophrenia. American Journal of Psychiatry, 2011, 168, 400-407.	4.0	147
312	Validating the Measurement of Real-World Functional Outcomes: Phase I Results of the VALERO Study. American Journal of Psychiatry, 2011, 168, 1195-1201.	4.0	168
313	Validating Measures of Real-World Outcome: The Results of the VALERO Expert Survey and RAND Panel. Schizophrenia Bulletin, 2011, 37, 334-343.	2.3	167
314	Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia. , 2011, , 33-74.		1
315	Assessment of everyday functioning in schizophrenia. Innovations in Clinical Neuroscience, 2011, 8, 21-4.	0.1	16
316	Mood symptoms, cognition, and everyday functioning: in major depression, bipolar disorder, and schizophrenia. Innovations in Clinical Neuroscience, 2011, 8, 14-8.	0.1	21
317	Relationship of the Brief UCSD Performanceâ€based Skills Assessment (UPSAâ€B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder. Bipolar Disorders, 2010, 12, 45-55.	1.1	106
318	Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disorders, 2010, 12, 364-375.	1.1	130
319	Social competence and observerâ€rated social functioning in bipolar disorder. Bipolar Disorders, 2010, 12, 843-850.	1.1	43
320	Prediction of Real-World Functional Disability in Chronic Mental Disorders: A Comparison of Schizophrenia and Bipolar Disorder. American Journal of Psychiatry, 2010, 167, 1116-1124.	4.0	394
321	Evaluation of Dementia Rating Scales in Parkinson's Disease Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 142-148.	0.9	16
322	Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies. Neuropsychopharmacology, 2010, 35, 1053-1062.	2.8	109
323	Pergolide Treatment of Cognitive Deficits Associated with Schizotypal Personality Disorder: Continued Evidence of the Importance of the Dopamine System in the Schizophrenia Spectrum. Neuropsychopharmacology, 2010, 35, 1356-1362.	2.8	51
324	The Course of Neuropsychological Performance and Functional Capacity in Older Patients with Schizophrenia: Influences of Previous History of Long-Term Institutional Stay. Biological Psychiatry, 2010, 67, 933-939.	0.7	75

#	Article	IF	CITATIONS
325	Cortical neuritic plaques and hippocampal neurofibrillary tangles are related to dementia severity in elderly schizophrenia patients. Schizophrenia Research, 2010, 116, 90-96.	1.1	30
326	Psychometric properties of performance-based measurements of functional capacity: Test–retest reliability, practice effects, and potential sensitivity to change. Schizophrenia Research, 2010, 119, 246-252.	1.1	67
327	Cognitive Functioning and Disability in Schizophrenia. Current Directions in Psychological Science, 2010, 19, 249-254.	2.8	23
328	Social cognition: the key factor predicting social outcome in people with schizophrenia?. Psychiatry, 2010, 7, 41-4.	0.3	39
329	Latest developments in the matrics process. Psychiatry, 2010, 7, 49-52.	0.3	7
330	Performance-Based Measurement of Functional Disability in Schizophrenia: A Cross-National Study in the United States and Sweden. American Journal of Psychiatry, 2009, 166, 821-827.	4.0	109
331	Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem. Schizophrenia Bulletin, 2009, 35, 403-414.	2.3	121
332	Functional Recovery in Schizophrenia: Raising the Bar for Outcomes in People with Schizophrenia. Schizophrenia Bulletin, 2009, 35, 299-299.	2.3	16
333	Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?. Journal of Affective Disorders, 2009, 119, 181-185.	2.0	145
334	Pharmacological Cognitive Enhancement in Schizophrenia. Neuropsychology Review, 2009, 19, 324-335.	2.5	86
335	Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disorders, 2009, 11, 113-125.	1.1	240
336	Letter to the Editor: reply to Magalhães etÂal Bipolar Disorders, 2009, 11, 901-901.	1.1	0
337	Abbreviated neuropsychological assessment in schizophrenia: Prediction of different aspects of outcome. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 462-471.	0.8	60
338	Toward a Terminology for Functional Recovery in Schizophrenia: Is Functional Remission a Viable Concept?. Schizophrenia Bulletin, 2009, 35, 300-306.	2.3	224
339	Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function. Schizophrenia Research, 2009, 107, 275-285.	1.1	40
340	Reduction of functional disability with atypical antipsychotic treatment: A randomized long term comparison of ziprasidone and haloperidol. Schizophrenia Research, 2009, 115, 24-29.	1.1	11
341	Determinants of everyday outcomes in schizophrenia: The influences of cognitive impairment, functional capacity, and symptoms. Schizophrenia Research, 2009, 115, 82-87.	1.1	197
342	Neuropsychological Function and Dysfunction in Schizophrenia and Psychotic Affective Disorders. Schizophrenia Bulletin, 2009, 35, 1022-1029.	2.3	427

#	Article	IF	CITATIONS
343	The Factor Structure of Clinical Symptoms in Depressed Inpatients With Unipolar or Bipolar Spectrum Disorders. Journal of Nervous and Mental Disease, 2009, 197, 161-165.	0.5	5
344	Is it possible to assess cognitive impairment other than with neuropsychological tests?. Psychiatry, 2009, 6, 23-5.	0.3	1
345	When does cognitive decline occur in the period prior to the first episode of schizophrenia?. Psychiatry, 2009, 6, 12-4.	0.3	9
346	Direct measurement of disability. Psychiatry, 2009, 6, 43-6.	0.3	3
347	The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment. Bipolar Disorders, 2008, 10, 900-906.	1.1	22
348	Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. Journal of Psychiatric Research, 2008, 42, 320-327.	1.5	116
349	Age-associated differences in cognitive performance in older community dwelling schizophrenia patients: Differential sensitivity of clinical neuropsychological and experimental information processing tests. Schizophrenia Research, 2008, 106, 50-58.	1.1	42
350	A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophrenia Research, 2008, 105, 138-143.	1.1	24
351	Introduction to the special section: The Eighth Biennial Mt. Sinai Conference on Cognition in Schizophrenia. Schizophrenia Research, 2008, 106, 1-2.	1.1	Ο
352	Communication abnormalities predict functional outcomes in chronic schizophrenia: Differential associations with social and adaptive functions. Schizophrenia Research, 2008, 103, 240-247.	1.1	97
353	Predicting Schizophrenia Patients' Real-World Behavior with Specific Neuropsychological and Functional Capacity Measures. Biological Psychiatry, 2008, 63, 505-511.	0.7	511
354	Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research, 2008, 102, 108-115.	1.1	281
355	Six-year outcomes in first admission adolescent inpatients: Clinical and cognitive characteristics at admission as predictors. Psychiatry Research, 2008, 160, 47-54.	1.7	13
356	The Broad Importance of Cognitive Impairments in Aging-Related Disorders. American Journal of Geriatric Psychiatry, 2008, 16, 99-101.	0.6	3
357	Neuropsychological and symptom predictors of aggression on the psychiatric inpatient service. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 700-709.	0.8	51
358	Is Schizophrenia a Syndrome of Accelerated Aging?. Schizophrenia Bulletin, 2008, 34, 1024-1032.	2.3	258
359	Diffusion Tensor Imaging Findings in First-Episode and Chronic Schizophrenia Patients. American Journal of Psychiatry, 2008, 165, 1024-1032.	4.0	227
360	Cognition and the differential diagnosis of schizophrenia. World Psychiatry, 2008, 7, 30-32.	4.8	4

#	Article	IF	CITATIONS
361	Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study. Journal of the International Neuropsychological Society, 2008, 14, 479-488.	1.2	97
362	Context processing in schizotypal personality disorder: Evidence of specificity of impairment to the schizophrenia spectrum Journal of Abnormal Psychology, 2008, 117, 342-354.	2.0	49
363	A Pilot Study of Adjunctive Atomoxetine Treatment to Second-Generation Antipsychotics for Cognitive Impairment in Schizophrenia. Journal of Clinical Psychopharmacology, 2008, 28, 59-63.	0.7	49
364	The genetics of cognitive impairment in schizophrenia. Psychiatry, 2008, 5, 65-7.	0.3	1
365	CNTRICS: Bringing Clinical Treatment Trials Closer to the Brain. Psychiatry, 2008, 5, 57-9.	0.3	0
366	Performance-Based Measures of Functional Skills: Usefulness in Clinical Treatment Studies. Schizophrenia Bulletin, 2007, 33, 1138-1148.	2.3	218
367	Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. Archives of General Psychiatry, 2007, 64, 633.	13.8	928
368	Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings Psychological Bulletin, 2007, 133, 833-858.	5.5	451
369	Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: Evidence for specificity of relationships?. Schizophrenia Research, 2007, 89, 330-338.	1.1	131
370	The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophrenia Research, 2007, 94, 99-106.	1.1	46
371	The Effects of Guanfacine on Context Processing Abnormalities in Schizotypal Personality Disorder. Biological Psychiatry, 2007, 61, 1157-1160.	0.7	62
372	Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders. Biological Psychiatry, 2007, 62, 226-234.	0.7	26
373	Schizophrenia: Measurements of Psychopathology. Psychiatric Clinics of North America, 2007, 30, 339-363.	0.7	24
374	Self-assessment of functional status in schizophrenia. Journal of Psychiatric Research, 2007, 41, 1012-1018.	1.5	213
375	Managing Cognitive Deficits and Functioning in Patients With Schizophrenia. Journal of Clinical Psychiatry, 2007, 68, e21.	1.1	2
376	Cognitive Functioning and Acute Sedative Effects of Risperidone and Quetiapine in Patients With Stable Bipolar I Disorder. Journal of Clinical Psychiatry, 2007, 68, 1186-1194.	1.1	42
377	The Latest Developments in the MATRICS Initiative. Psychiatry, 2007, 4, 29-31.	0.3	2
378	Is cognitive impairment in schizophrenia multidimensional?: implications for assessment and treatment. Psychiatry, 2007, 4, 50-2.	0.3	0

#	Article	IF	CITATIONS
379	Cognitive Outcomes in the CATIE Schizophrenia Trial: Why do they seem different from previous results?. Psychiatry, 2007, 4, 20-3.	0.3	4
380	Will improving cognition change functional outcomes in schizophrenia?. Psychiatry, 2007, 4, 58-60.	0.3	1
381	Cognitive impairments in major depression and bipolar disorders. Psychiatry, 2007, 4, 12-4.	0.3	7
382	Administration and interpretation of the Trail Making Test. Nature Protocols, 2006, 1, 2277-2281.	5.5	942
383	Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia. Drugs, 2006, 66, 1465-1473.	4.9	27
384	Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: A population-based study. Schizophrenia Research, 2006, 85, 49-57.	1.1	47
385	Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: Retrospective comparison of first generation and second generation antipsychotics. Schizophrenia Research, 2006, 88, 127-134.	1.1	18
386	Dual-task information processing in schizotypal personality disorder: Evidence of impaired processing capacity Neuropsychology, 2006, 20, 453-460.	1.0	19
387	Convergence of Clinical Staff Ratings and Research Ratings to Assess Patients With Schizophrenia in Nursing Homes. Psychiatric Services, 2006, 57, 838-843.	1.1	8
388	Neuropsychological Normalization With Long-Term Atypical Antipsychotic Treatment: Results of a Six-Month Randomized, Double-Blind Comparison of Ziprasidone vs. Olanzapine. Journal of Neuropsychiatry and Clinical Neurosciences, 2006, 18, 54-63.	0.9	36
389	The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. Psychopharmacology, 2006, 187, 356-363.	1.5	55
390	Cognitive impairment in the schizophrenia spectrum: What is the evidence for similarity to schizophrenia?. Current Psychosis & Therapeutics Reports, 2006, 4, 128-133.	0.1	0
391	The Relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to Functional Capacity and Real-world Functional Outcome. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 260-269.	0.8	129
392	Validity and Stability of Performance-Based Estimates of Premorbid Educational Functioning in Older Patients with Schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 178-192.	0.8	33
393	Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial. Neuropsychopharmacology, 2006, 31, 2033-2046.	2.8	408
394	The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity. American Journal of Psychiatry, 2006, 163, 426-432.	4.0	325
395	Improvement in Social Competence With Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition, and Neuropsychological Functioning. American Journal of Psychiatry, 2006, 163, 1918-1925.	4.0	105
396	Negative Symptoms and Cognitive Deficits: What Is the Nature of Their Relationship?. Schizophrenia Bulletin, 2006, 32, 250-258.	2.3	379

#	Article	IF	CITATIONS
397	Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms. American Journal of Psychiatry, 2006, 163, 418-425.	4.0	660
398	Premorbid Intellectual Functioning and Risk of Schizophrenia and Spectrum Disorders. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 193-207.	0.8	86
399	Cognition and Aging in Psychopathology: Focus on Schizophrenia and Depression. Annual Review of Clinical Psychology, 2006, 2, 389-409.	6.3	40
400	Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatric Disease and Treatment, 2006, 2, 531-536.	1.0	420
401	Outcomes to Monitor When Treating Bipolar Disorder or Schizophrenia. Journal of Clinical Psychiatry, 2006, 67, e06.	1.1	4
402	Cognitive and Functional Effects of Atypical Antipsychotic Medications. Journal of Clinical Psychiatry, 2006, 67, e13.	1.1	41
403	Current Status of the MATRICS/ TURNS Initiative. Psychiatry, 2006, 3, 24-33.	0.3	1
404	Defining and achieving recovery from bipolar disorder. Journal of Clinical Psychiatry, 2006, 67 Suppl 9, 14-8; discussion 36-42.	1.1	6
405	From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone. CNS Spectrums, 2005, 10, 1-20.	0.7	36
406	The Validation of a Caregiver Assessment of Dementia. Alzheimer Disease and Associated Disorders, 2005, 19, 186-194.	0.6	15
407	Stability in schizophrenia symptoms over time: Findings from the Mount Sinai Pilgrim Psychiatric Center Longitudinal Study Journal of Abnormal Psychology, 2005, 114, 363-372.	2.0	40
408	Optimizing Treatment of Schizophrenia Enhancing Affective/Cognitive and Depressive Functioning. CNS Spectrums, 2005, 10, 1-1.	0.7	24
409	Cognitive Impairment in Schizophrenia. CNS Spectrums, 2005, 10, 7-9.	0.7	3
410	Neurocognition, Symptomatology, and Functional Skills in Older Alcohol-Abusing Schizophrenia Patients. Schizophrenia Bulletin, 2005, 31, 175-182.	2.3	56
411	The Longitudinal Course of Thought Disorder in Geriatric Patients With Chronic Schizophrenia. American Journal of Psychiatry, 2005, 162, 793-795.	4.0	42
412	Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study. American Journal of Psychiatry, 2005, 162, 110-117.	4.0	51
413	Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a Large Long-Term Trial. American Journal of Psychiatry, 2005, 162, 1888-1895.	4.0	148
414	Rates and Predictors of Adherence with Atypical Antipsychotic Medication: AFollow-Up Study of Adolescent Inpatients. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 901-912.	0.7	48

#	Article	IF	CITATIONS
415	Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. Expert Opinion on Pharmacotherapy, 2005, 6, 337-346.	0.9	20
416	Depressed mood and its functional correlates in institutionalized schizophrenia patients. Schizophrenia Research, 2005, 77, 179-187.	1.1	20
417	Cognition in Schizophrenia: Impairments, Determinants, and Functional Importance. Psychiatric Clinics of North America, 2005, 28, 613-633.	0.7	207
418	Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology, 2004, 172, 324-332.	1.5	74
419	Stability and Functional Correlates of Memory-Based Classification in Older Schizophrenia Patients. American Journal of Geriatric Psychiatry, 2004, 12, 376-386.	0.6	18
420	The relationship of neuropsychological test performance with the PANSS in antipsychotic naÃ ⁻ ve, first-episode psychosis patients. Schizophrenia Research, 2004, 68, 11-19.	1.1	55
421	Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophrenia Research, 2004, 66, 101-113.	1.1	83
422	The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research, 2004, 68, 283-297.	1.1	1,209
423	Disability Reduction in Elderly Patients with Schizophrenia. Journal of Psychiatric Practice, 2004, 10, 283-295.	0.3	5
424	Context-Processing Deficits in Schizotypal Personality Disorder Journal of Abnormal Psychology, 2004, 113, 556-568.	2.0	88
425	Cognitive Functioning in Schizophrenia. Journal of Clinical Psychiatry, 2004, 65, 361-372.	1.1	191
426	Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Journal of Clinical Psychiatry, 2004, 65, 361-72.	1.1	59
427	Cognitive functioning in schizophrenia. Current Psychosis & Therapeutics Reports, 2003, 1, 22-27.	0.1	0
428	Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology, 2003, 169, 404-411.	1.5	132
429	Cognition in schizophrenia: from basic science to clinical treatment. Psychopharmacology, 2003, 169, 213-214.	1.5	20
430	Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. International Journal of Geriatric Psychiatry, 2003, 18, 820-829.	1.3	67
431	Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study. Schizophrenia Research, 2003, 59, 243-251.	1.1	27
432	Convergence of Different Versions of the Continuous Performance Test: Clinical and Scientific Implications. Journal of Clinical and Experimental Neuropsychology, 2003, 25, 283-292.	0.8	56

#	Article	IF	CITATIONS
433	Commentary: Chickens and Eggs; Carts and Horses: An Outsider's Perspective on the Study of the Early Stages and Potential Prevention of Psychosis and Schizophrenia. Schizophrenia Bulletin, 2003, 29, 845-849.	2.3	4
434	The Course of Functional Decline in Geriatric Patients With Schizophrenia: Cognitive-Functional and Clinical Symptoms as Determinants of Change. American Journal of Geriatric Psychiatry, 2003, 11, 610-619.	0.6	59
435	Ziprasidone and cognition: the evolving story. Journal of Clinical Psychiatry, 2003, 64 Suppl 19, 33-9.	1.1	3
436	Cortical and Subcortical Cognitive Deficits in Schizophrenia: Convergence of Classifications Based on Language and Memory Skill Areas. Journal of Clinical and Experimental Neuropsychology, 2002, 24, 55-66.	0.8	18
437	Correlates of Change in Functional Status of Institutionalized Geriatric Schizophrenic Patients: Focus on Medical Comorbidity. American Journal of Psychiatry, 2002, 159, 1388-1394.	4.0	69
438	Relationship Between Premorbid Functioning and Symptom Severity as Assessed at First Episode of Psychosis. American Journal of Psychiatry, 2002, 159, 2021-2026.	4.0	86
439	A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry, 2002, 51, 349-357.	0.7	170
440	The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. Comprehensive Psychiatry, 2001, 42, 306-313.	1.5	57
441	Diagnosis of manic episodes in adolescent inpatients: structured diagnostic procedures compared to clinical chart diagnoses. Psychiatry Research, 2001, 101, 47-54.	1.7	58
442	Aggression in Elderly Schizophrenia Patients. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 357-366.	0.9	21
443	Cognition in schizophrenia. Current Psychiatry Reports, 2001, 3, 423-428.	2.1	74
444	Cognitive impairment in elderly patients with schizophrenia: age related changes. International Journal of Geriatric Psychiatry, 2001, 16, S78-S85.	1.3	39
445	Guanfacine Treatment of Cognitive Impairment in Schizophrenia. Neuropsychopharmacology, 2001, 25, 402-409.	2.8	103
446	Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment. American Journal of Psychiatry, 2001, 158, 176-184.	4.0	581
447	Six-Year Follow-Up Study of Cognitive and Functional Status Across the Lifespan in Schizophrenia: A Comparison With Alzheimer's Disease and Normal Aging. American Journal of Psychiatry, 2001, 158, 1441-1448.	4.0	233
448	Relationship of Cognitive Functioning, Adaptive Life Skills, and Negative Symptom Severity in Poor-Outcome Geriatric Schizophrenia Patients. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 257-264.	0.9	32
449	Neuropsychological Differences Between First-Admission Schizophrenia and Psychotic Affective Disorders. American Journal of Psychiatry, 2000, 157, 1453-1460.	4.0	115
450	Practice-related improvement in information processing with novel antipsychotic treatment. Schizophrenia Research, 2000, 46, 139-148.	1.1	64

#	Article	IF	CITATIONS
451	Visuospatial working memory in schizotypal personality disorder patients. Schizophrenia Research, 2000, 41, 447-455.	1.1	75
452	Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. Biological Psychiatry, 2000, 47, 962-968.	0.7	56
453	Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biological Psychiatry, 1999, 45, 32-40.	0.7	222
454	Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophrenia Research, 1999, 35, 77-84.	1.1	103
455	Memory performance of geriatric and nongeriatric chronic schizophrenic patients: A cross-sectional study. Journal of the International Neuropsychological Society, 1999, 5, 494-501.	1.2	20
456	Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. , 1998, 13, 473-479.		42
457	Age-related shift in brain region activity during successful memory performance. Neurobiology of Aging, 1998, 19, 437-445.	1.5	104
458	Symptoms, Cognitive Functioning, and Adaptive Skills in Geriatric Patients With Lifelong Schizophrenia: A Comparison Across Treatment Sites. American Journal of Psychiatry, 1998, 155, 1080-1086.	4.0	310
459	Learning and memory in adolescent psychiatric inpatients with major depression: A normative study of the California verbal learning test. Archives of Clinical Neuropsychology, 1997, 12, 575-584.	0.3	18
460	Association of MMPI Validity Scales and Therapist Ratings of Psychopathology in Adolescent Psychiatric Inpatients. Assessment, 1997, 4, 17-27.	1.9	7
461	Noncognitive Disturbances in Alzheimer's Disease: Frequency, Longitudinal Course, and Relationship to Cognitive Symptoms. Journal of the American Geriatrics Society, 1997, 45, 1331-1338.	1.3	89
462	The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients. Schizophrenia Research, 1997, 27, 211-218.	1.1	52
463	Empirical Assessment of the Factorial Structure of Clinical Symptoms in Schizophrenia. Psychopathology, 1997, 30, 263-274.	1.1	334
464	CHARACTERISTICS OF ELDERLY PSYCHIATRIC PATIENTS RETAINED IN A STATE HOSPITAL DURING DOWNSIZING: A PROSPECTIVE STUDY WITH REPLICATION. , 1997, 12, 474-480.		39
465	Cognitive impairment in geriatric chronic schizophrenic patients: a cross-national study in New York and London. , 1997, 12, 1001-1007.		27
466	Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophrenia Research, 1996, 22, 223-231.	1.1	115
467	Information-processing markers of vulnerability to schizophrenia: performance of patients with schizotypal and nonschizotypal personality disorders. Psychiatry Research, 1996, 60, 49-56.	1.7	45
468	Symptom stability in geriatric chronic schizophrenic inpatients: A one-year follow-up study. Biological Psychiatry, 1996, 39, 92-99.	0.7	42

#	Article	IF	CITATIONS
469	Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the brief psychiatric rating scale. Biological Psychiatry, 1996, 40, 755-760.	0.7	36
470	Performance of chronic schizophrenic patients on cognitive neuropsychological measures sensitive to dementia. International Journal of Geriatric Psychiatry, 1996, 11, 621-627.	1.3	28
471	The Longitudinal Stability of Cognitive Impairment in Schizophrenia. British Journal of Psychiatry, 1995, 166, 630-633.	1.7	85
472	Empirical evaluation of the factorial structure of attention in adolescent psychiatric patients. Journal of Clinical and Experimental Neuropsychology, 1994, 16, 344-353.	0.8	20
473	A multimethod, multichannel assessment of affective flattening in schizophrenia. Psychiatry Research, 1994, 54, 211-222.	1.7	42
474	Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. Psychiatry Research, 1994, 53, 1-12.	1.7	133
475	Cognitive Deficits in Schizophrenia. Psychiatric Clinics of North America, 1993, 16, 295-312.	0.7	274
476	Psychometric vs. attentional correlates of early onset alcohol and substance abuse. Journal of Abnormal Child Psychology, 1992, 20, 151-162.	3.5	17
477	Medication may be required for the development of automatic information processing in schizophrenia. Psychiatry Research, 1990, 32, 281-288.	1.7	56
478	The affective lability scales: Development, reliability, and validity. Journal of Clinical Psychology, 1989, 45, 786-793.	1.0	278
479	Distractibility in children vulnerable to psychopathology Journal of Abnormal Psychology, 1981, 90, 298-304.	2.0	119
480	The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date. , 0, , 177-191.		0
481	Cognitive functioning and awareness of illness in schizophrenia: a review and meta-analysis. , 0, , 142-160.		3
482	Cognition and functional status in adult and older patients with schizophrenia. , 0, , 110-125.		1
483	Performance-based measures of functioning in schizophrenia. , 0, , 247-265.		0